Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children

Medical Oncology

Volumn 22, Issue 1, 2005, Pages 79-88

  Pospíšilová, Dagmar ^a   Borovičková, Jiřina ^a   Rožková, Daniela ^a   Starý, Jan ^a   Seifertová, Daniela ^a   Tobiásová, Zuzana ^a   Špíšek, Radek ^a   Bartůňková, Jiřina ^a,b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute lymphoblastic leukemia; Dendritic cells; Immunotherapy; Leukemic blasts

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL CULTURE; CELL MATURATION; CELL STIMULATION; CELL STRUCTURE; CELL VIABILITY; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INFANT; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MORPHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; REMISSION; STEM CELL; TREATMENT OUTCOME;

EID: 18444387725     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/mo:22:1:079     Document Type: Article

References (28)

1. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-1630.
2. Campana D, Neale GA, Coustan-Smith E, Pui CH. Detection of minimal residual disease in acute lymphoblastic leukemia: the St Jude experience. Leukemia 2001; 15:278-279.
3. Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br JHaematol 1993; 83:412-418.
4. Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D. New approaches in the immunotherapy of haematological malignancies. Eur J Haematol 2003; 70:333-345.
5. Kedar E, Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 1992;59:245-322.
6. Champlin R. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol 1995; 23:1148-1151.
7. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD, Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity [see comments]. J Exp Med 1996; 183:283-287.
8. Tsai V, Kawashima I, Keogh E, Daly K, Sette A, Celis E. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998; 18:65-75.
9. Murphy GP, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39:54-59.
10. Holtl L, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161:777-782.
11. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [see comments]. Nat Med 1998; 4:328-332.
12. Panelli MC, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000; 23:487-498.
13. Choudhury A, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133-1142.
14. Choudhury BA, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93:780-786.
15. Vuillier F, Maloum K, Thomas EK, Jouanne C, Dighiero G, Scott-Algara D. Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia. Br J Haematol 2001; 115:831-844.
16. Spisek R, et al. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002; 62:2861-2868.
17. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 2001; 97:2764-2771.
18. Cardoso AA, et al. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood 1999; 94:3531-3540.
19. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 1999; 94:2048-2055.
20. Osman Y, et al. Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Oncol Rep 1999; 6:1057-1063.
21. Mohty M, et al. Generation of potent T(h)1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells. Int Immunol 2002; 14:741-750.
22. Pospisilova D, et al. Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother 2002; 51:72-78.
23. Spisek R, Bretaudeau L, Barbieux I, Meflah K, Gregoire M. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use. Cancer Immunol Immunother 2001; 50:417-427.
24. Panoskaltsis N, Belanger TJ, Liesveld JL, Abboud CN. Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells in short-term culture. Leuk Res 2002; 26:191-201.
25. Letarte M, et al. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med 1988; 168:1247-1253.
26. Hsu FJ, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-58.
27. Barratt-Boyes SM, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164:2487-2495.
28. Morse MA, Mosca PJ, Clay TM, Lyerly HK. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther 2002; 2:35-43.